See more : Cache Exploration Inc. (CEXPF) Income Statement Analysis – Financial Results
Complete financial analysis of Allergy Therapeutics plc (AGYTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allergy Therapeutics plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Beijing Hengyu Datacom Aviation Equipment co., LTD. (300965.SZ) Income Statement Analysis – Financial Results
- Investor AB (INVEAS.XD) Income Statement Analysis – Financial Results
- Tokyo Printing Ink Mfg. Co., Ltd. (4635.T) Income Statement Analysis – Financial Results
- Robot Home, Inc. (1435.T) Income Statement Analysis – Financial Results
- CANADIAN LARGE CAP LEADERS SPLI (NPS.TO) Income Statement Analysis – Financial Results
Allergy Therapeutics plc (AGYTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.allergytherapeutics.com
About Allergy Therapeutics plc
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.20M | 59.59M | 72.77M | 84.33M | 78.20M | 73.72M | 68.35M | 64.14M | 48.51M | 43.23M | 41.96M | 39.28M | 41.28M | 41.55M | 40.75M | 37.76M | 31.02M | 25.74M | 23.56M | 20.61M | 18.00M | 17.33M | 15.14M |
| Cost of Revenue | 25.46M | 26.34M | 23.26M | 22.11M | 20.20M | 18.38M | 17.01M | 16.77M | 14.07M | 12.18M | 11.95M | 11.95M | 13.67M | 13.22M | 11.16M | 13.56M | 10.87M | 10.07M | 6.51M | 4.85M | 5.51M | 5.33M | 5.27M |
| Gross Profit | 29.74M | 33.25M | 49.51M | 62.23M | 58.00M | 55.34M | 51.33M | 47.37M | 34.44M | 31.05M | 30.00M | 27.33M | 27.61M | 28.33M | 29.59M | 24.19M | 20.16M | 15.67M | 17.05M | 15.75M | 12.49M | 12.00M | 9.87M |
| Gross Profit Ratio | 53.87% | 55.79% | 68.03% | 73.79% | 74.17% | 75.07% | 75.11% | 73.85% | 71.00% | 71.83% | 71.51% | 69.57% | 66.88% | 68.18% | 72.60% | 64.08% | 64.98% | 60.89% | 72.35% | 76.45% | 69.37% | 69.26% | 65.18% |
| Research & Development | 22.90M | 20.12M | 15.66M | 12.89M | 5.85M | 6.95M | 16.02M | 9.30M | 16.22M | 3.12M | 2.96M | 2.54M | 2.10M | 1.67M | 2.21M | 5.30M | 16.30M | 25.34M | 9.56M | 5.62M | 451.00K | 527.00K | 2.54M |
| General & Administrative | 22.79M | 25.18M | 20.83M | 20.67M | 19.63M | 17.60M | 15.54M | 13.78M | 10.09M | 10.22M | 7.99M | 7.85M | 15.18M | -8.29M | -6.03M | -14.74M | -12.71M | -11.14M | -6.81M | -4.96M | -2.23M | 0.00 | 0.00 |
| Selling & Marketing | 19.59M | 23.71M | 26.00M | 25.20M | 24.85M | 27.00M | 27.13M | 26.89M | 20.22M | 17.06M | 17.92M | 16.28M | 17.88M | 17.52M | 16.14M | 14.89M | 12.85M | 11.31M | 9.83M | 8.01M | 6.57M | 0.00 | 0.00 |
| SG&A | 42.38M | 48.88M | 46.83M | 45.87M | 44.48M | 44.59M | 42.68M | 40.67M | 30.32M | 27.28M | 25.91M | 24.12M | 33.06M | 9.23M | 10.12M | 158.00K | 147.00K | 169.00K | 3.03M | 3.05M | 4.34M | 0.00 | 0.00 |
| Other Expenses | -287.00K | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -154.00K | -171.00K | -191.00K | 0.00 | 0.00 | 0.00 | -196.00K | -193.00K | 3.37M | 367.00K | 31.00K | -350.00K | -262.00K | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 64.99M | 72.90M | 61.75M | 58.19M | 49.69M | 50.95M | 58.06M | 49.26M | 46.39M | 30.33M | 28.80M | 26.66M | 35.16M | 28.39M | 28.01M | 32.68M | 44.71M | 50.92M | 24.80M | 18.95M | 10.93M | 13.57M | 14.07M |
| Cost & Expenses | 90.46M | 99.24M | 85.01M | 80.30M | 69.90M | 69.33M | 75.08M | 66.03M | 60.46M | 42.51M | 40.75M | 38.61M | 48.83M | 41.62M | 39.17M | 46.25M | 55.58M | 60.99M | 31.31M | 23.81M | 16.45M | 18.90M | 19.34M |
| Interest Income | 285.00K | 329.00K | 257.00K | 117.00K | 266.00K | 103.00K | 154.00K | 151.00K | 180.00K | 147.00K | 170.00K | 19.00K | 5.00K | 2.00K | 9.00K | 30.00K | 201.00K | 647.00K | 545.00K | 531.00K | 60.00K | 33.00K | 24.00K |
| Interest Expense | 4.11M | 2.44M | 669.00K | 491.00K | 504.00K | 201.00K | 320.00K | 225.00K | 293.00K | 218.00K | 308.00K | 404.00K | 457.00K | 1.54M | 1.79M | 3.24M | 1.97M | 131.00K | 4.00K | 42.00K | 26.00K | 39.00K | 545.00K |
| Depreciation & Amortization | 4.32M | 4.22M | 4.17M | 4.13M | 3.91M | 2.09M | 2.02M | 1.94M | 1.67M | 1.29M | 1.29M | 1.34M | 1.89M | 1.70M | 1.43M | 1.32M | 1.16M | 955.00K | 1.12M | 884.00K | 319.00K | 944.00K | 1.92M |
| EBITDA | -30.74M | -35.10M | -7.82M | 8.28M | 12.49M | 6.58M | -4.56M | 191.00K | -10.56M | 2.17M | 2.68M | 2.03M | 2.99M | 727.00K | 3.10M | -6.89M | -17.11M | -24.67M | -5.38M | -1.00M | 1.94M | 5.24M | -2.31M |
| EBITDA Ratio | -55.69% | -58.91% | -10.75% | 9.82% | 15.97% | 8.93% | -6.67% | 0.30% | -20.83% | 5.01% | 6.35% | 5.17% | 7.24% | 0.70% | 7.19% | -15.11% | -55.17% | -95.76% | -21.40% | -6.11% | 10.75% | 13.49% | -14.93% |
| Operating Income | -35.26M | -39.65M | -12.25M | 4.03M | 8.31M | 4.39M | -6.73M | -1.90M | -11.95M | 725.00K | 1.21M | 668.00K | 1.09M | 115.00K | 1.46M | 5.10M | 15.59M | 26.28M | 6.71M | 2.42M | 1.56M | 1.39M | 4.25M |
| Operating Income Ratio | -63.87% | -66.55% | -16.83% | 4.78% | 10.62% | 5.96% | -9.85% | -2.96% | -24.64% | 1.68% | 2.88% | 1.70% | 2.65% | 0.28% | 3.57% | 13.52% | 50.26% | 102.07% | 28.50% | 11.73% | 8.64% | 8.04% | 28.08% |
| Total Other Income/Expenses | -3.91M | -2.11M | -412.00K | -374.00K | -238.00K | -98.00K | -166.00K | -74.00K | -113.00K | -71.00K | -125.00K | -139.00K | -452.00K | -2.43M | -1.57M | -16.54M | -35.84M | -52.03M | -12.89M | -4.61M | 34.00K | 2.87M | -9.02M |
| Income Before Tax | -39.17M | -41.77M | -12.66M | 3.66M | 8.07M | 4.29M | -6.90M | -1.97M | -12.06M | 654.00K | 1.08M | 432.00K | 640.00K | -2.31M | -116.00K | -11.44M | -20.24M | -25.76M | -6.17M | -2.19M | 1.59M | 4.26M | -4.77M |
| Income Before Tax Ratio | -70.95% | -70.09% | -17.39% | 4.34% | 10.32% | 5.82% | -10.09% | -3.07% | -24.87% | 1.51% | 2.58% | 1.10% | 1.55% | -5.57% | -0.28% | -30.29% | -65.26% | -100.07% | -26.20% | -10.63% | 8.83% | 24.58% | -31.52% |
| Income Tax Expense | 1.05M | 1.31M | 1.12M | 771.00K | 1.01M | 826.00K | 637.00K | 511.00K | 1.01M | 546.00K | 343.00K | -104.00K | -183.00K | 349.00K | -702.00K | 326.00K | 53.00K | -2.50M | -12.87M | -4.56M | 372.00K | -916.00K | -109.00K |
| Net Income | -40.22M | -43.07M | -13.78M | 2.89M | 7.06M | 3.47M | -7.53M | -2.48M | -13.07M | 108.00K | 741.00K | 633.00K | 823.00K | -2.66M | 586.00K | -11.76M | -20.30M | -23.26M | -6.17M | -2.19M | 1.22M | 5.18M | -4.66M |
| Net Income Ratio | -72.86% | -72.28% | -18.93% | 3.42% | 9.03% | 4.70% | -11.02% | -3.87% | -26.95% | 0.25% | 1.77% | 1.61% | 1.99% | -6.41% | 1.44% | -31.16% | -65.43% | -90.34% | -26.20% | -10.63% | 6.77% | 29.87% | -30.80% |
| EPS | 0.00 | -0.06 | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| EPS Diluted | 0.00 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| Weighted Avg Shares Out | 0.00 | 669.84M | 1.40B | 1.39B | 1.38B | 1.37B | 595.10M | 592.19M | 570.34M | 475.20M | 451.54M | 408.39M | 326.80M | 310.76M | 293.14M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 40.94M | 62.95M | 62.95M |
| Weighted Avg Shares Out (Dil) | 0.00 | 670.36M | 1.40B | 1.47B | 1.46B | 1.45B | 595.10M | 592.19M | 570.34M | 498.24M | 471.51M | 427.02M | 340.05M | 323.35M | 305.58M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 49.29M | 62.95M | 62.95M |
Allergy Therapeutics unveils encouraging early data from peanut trial
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced encouraging interim findings from its phase I/IIa VLP Peanut PROTECT trial aimed at addressing peanut allergies using a nanoparticle-based treatment. The study's early data shows that VLP Peanut could reduce sensitivity to peanuts and...
Allergy Therapeutics begins paediatric trial for grass allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its Grass MATA MPL allergy treatment in children. This marks the first industry trial of its kind for paediatric patients with...
Allergy Therapeutics applies for full marketing approval for grass allergy jab
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) marked a 'significant milestone' after it applied for regulatory approval of its new grass allergy immunotherapy. The submission, made to Germany's Paul Ehrlich Institut (PEI), includes evidence from a phase III clinical trial showing significant symptom reduction...
Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%
The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market Size is Expected to Reach USD 42.5 Billion by 2033, according to a research report published by Spherical Insights &...
Allergy Therapeutics jumps 23% on success of grass allergy vaccine trial
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) shares gesundheited 23% higher to a six-month peak of 1.83p after reporting success from a pivotal phase III trial to test its grass allergy vaccine, Grass MATA MPL. This short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate aims...
Allergy Therapeutics to present key scientific findings from its research portfolio
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has said it will be presenting key scientific findings from its research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, held in Hamburg, Germany from June 9 to 11, 2023. The...
Allergy Therapeutics peanut vaccine candidate negotiates its early clinical hurdle
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced a significant milestone in its innovative peanut allergy treatment with the successful completion of skin-prick testing on peanut-allergic patients in the phase I PROTECT clinical trial. The results indicate a substantial reduction in...
Allergy Therapeutics agrees bail out by two large shareholders
Allergy Therapeutics has arranged a financing package from two of the major shareholders that will enable it to carry on with planned trials of its hay fever and peanut vaccines. ZQ Capital and Southern Fox are making direct equity subscriptions...
Allergy Therapeutics doses first patients with peanut allergy vaccine
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the commercial-stage biotech company, has started administering its groundbreaking short-course peanut allergy vaccine candidate, VLP Peanut, to phase I PROTECT trial patients. The first-of-its-kind study aims to evaluate the safety, tolerability, and preliminary efficacy of VLP...
Allergy Therapeutics confident about the direction of funding discussions
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it expects revenue for the first six months to be £39.9mln, down 18% compared to the same period last year. The decrease in revenue is primarily due to a voluntary short-term pause in production...
Source: https://incomestatements.info
Category: Stock Reports